After more than 50 years, humans are flying back to the moon. The Artemis II lunar flyby is scheduled for Easter Monday, marking a rebirth for human spaceflight.
Get the latest international news and world events from around the world.
We Are As Gods: Steven Kotler on Our Godlike Power, Stone Age Minds
Do we have godlike responsibility to match?
In this third conversation with Steven Kotler — our first in 14 years — we dig into his latest book, We Are As Gods: A Survival Guide for the Age of Abundance, co-written with Peter Diamandis. And while the book makes a powerful case for abundance, I came prepared to challenge it.
Because abundance without purpose, as Kotler himself argues, is not salvation. It is a different kind of crisis.
Some black holes are ‘forbidden,’ ripples in spacetime reveal
How do you prove that in the unimaginably vast universe, certain objects don’t exist?
That’s a question that has plagued scientists studying gravitational waves—ripples in spacetime set off when two massive objects such as black holes swirl together and merge.
For decades, theorists have thought that, ironically, stars in a certain very heavy mass range simply cannot collapse to form black holes.
But gravitational wave astronomers had spotted no evidence of such a “mass gap”—until now.
Analysis of gravitational waves supports theory that some stars explode without leaving behind black holes.
Mesothelioma: a systemic therapy clinical trials snapshot
Systemic therapy targets in mesothelioma.
Recent changes to clinical practice have made modest improvements in 1– 2-year survival, but longer-term survival remains unchanged, and durable benefit is very rare.
Combining immunotherapy with chemotherapy, particularly with novel bispecific agents, may result in more therapeutic modalities being administered together in the first-line setting. The current evidence for second-line treatments is sparse.
New targeted-therapy strategies are promising. Early-phase clinical trials are showing signals of efficacy in mesotheliomas harboring MTAP loss or inactivation of the Hippo pathway.
Further studies will be needed to robustly confirm clinical benefit. sciencenewshighlights ScienceMission https://sciencemission.com/Mesothelioma
Mesothelioma is a rare cancer that has seen few incremental improvements in survival over the past two decades. However, a significantly improved understanding of the underlying biology has led to new therapeutic advances with the potential to improve clinical outcomes. In this review, we take a snapshot of the current systemic therapy research landscape, with our goal to forecast the trajectory of drug development for mesothelioma over the next half-decade. In our current census, we identify 106 active trials including systemic therapies: 20 (19%) are molecularly targeted, 26 (25%) include immunomodulation, and 12 (11%) combining immunotherapy with antiangiogenic therapies. Collectively, the landscape of therapeutic innovation for mesothelioma is expanding, bringing hope that improvements in life expectancy may follow.
Molecular Markers of Blood Cell Populations Can Help Estimate Aging of the Immune System
Aging of the immune system involves functional changes in individual cell populations, in hematopoietic tissues and at the systemic level. They are mediated by factors produced by circulating cells, niche cells, and at the systemic level. Age-related alterations in the microenvironment of the bone marrow and thymus cause a decrease in the production of naive immune cells and functional immunodeficiencies. Another result of aging and reduced tissue immune surveillance is the accumulation of senescent cells. Some viral infections deplete adaptive immune cells, increasing the risk of autoimmune and immunodeficiency conditions, leading to a general degradation in the specificity and effectiveness of the immune system in old age.
Mineral and bone effects of EPT
Highlighting the potential of PTH1R receptor agonist therapy in autosomal dominant hypocalcemia type 1
https://doi.org/10.1172/JCI201759 In this Research Letter, Rajesh V. Thakker & team report on the use of Eneboparatide in mice with ADH1, which increased serum calcium levels without increasing urine calcium.
3Mary Lyon Centre, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, United Kingdom.
4Endocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
5William Harvey Research Institute, London School of Medicine, Queen Mary University of London, London, United Kingdom.